Do Anti-androgens Have Potential as Therapeutics for COVID-19?

DOI record: { "DOI": "10.1210/endocr/bqab114", "ISSN": [ "0013-7227", "1945-7170" ], "URL": "http://dx.doi.org/10.1210/endocr/bqab114", "abstract": "<jats:title>Abstract</jats:title>\n <jats:p>Coronavirus disease 2019 (COVID-19) is characterized by a gender disparity in severity, with men exhibiting higher hospitalization and mortality rates than women. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, infects cells following recognition and attachment of the viral spike glycoprotein to the angiotensin-converting enzyme 2 transmembrane protein, followed by spike protein cleavage and activation by cell surface transmembrane protease serine 2 (TMPRSS2). In prostate cancer cells, androgen acting on the androgen receptor increases TMPRSS2 expression, which has led to the hypothesis that androgen-dependent expression of TMPRSS2 in the lung may increase men’s susceptibility to severe COVID-19 and that, accordingly, suppressing androgen production or action may mitigate COVID-19 severity by reducing SARS-CoV-2 amplification. Several ongoing clinical trials are testing the ability of androgen deprivation therapies or anti-androgens to mitigate COVID-19.</jats:p>\n <jats:p>This perspective discusses clinical and molecular advances on the rapidly evolving field of androgen receptor (AR) action on cell surface transmembrane protease serine 2 (TMPRSS2) expression and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and the potential effect of anti-androgens on coronavirus disease 2019 (COVID-19) severity in male patients. It discusses limitations of current studies and offers insight for future directions.</jats:p>", "author": [ { "ORCID": "http://orcid.org/0000-0002-0874-0754", "affiliation": [ { "name": "Department of Medicine, Section of Endocrinology, Tulane University School of Medicine, New Orleans, LA, USA" }, { "name": "Tulane Center of Excellence in Sex-Based Biology & Medicine, New Orleans, LA, USA" }, { "name": "Southeast Louisiana VA Medical Center, New Orleans, LA, USA" } ], "authenticated-orcid": false, "family": "Mauvais-Jarvis", "given": "Franck", "sequence": "first" } ], "container-title": "Endocrinology", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2021, 6, 5 ] ], "date-time": "2021-06-05T16:28:36Z", "timestamp": 1622910516000 }, "deposited": { "date-parts": [ [ 2021, 12, 17 ] ], "date-time": "2021-12-17T19:26:56Z", "timestamp": 1639769216000 }, "funder": [ { "DOI": "10.13039/100000002", "award": [ "DK074970", "DK107444" ], "doi-asserted-by": "publisher", "name": "National Institutes of Health" }, { "award": [ "7-20-COVID-051" ], "name": "American Diabetes Association COVID-19 Research Award" }, { "award": [ "BX003725" ], "name": "US Department of Veterans Affairs Merit Review Award" }, { "name": "Tulane Center of Excellence in Sex-Based Biology & Medicine" } ], "indexed": { "date-parts": [ [ 2024, 3, 5 ] ], "date-time": "2024-03-05T19:30:14Z", "timestamp": 1709667014378 }, "is-referenced-by-count": 11, "issue": "8", "issued": { "date-parts": [ [ 2021, 6, 5 ] ] }, "journal-issue": { "issue": "8", "published-print": { "date-parts": [ [ 2021, 8, 1 ] ] } }, "language": "en", "license": [ { "URL": "https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 6, 5 ] ], "date-time": "2021-06-05T00:00:00Z", "timestamp": 1622851200000 } } ], "link": [ { "URL": "http://academic.oup.com/endo/advance-article-pdf/doi/10.1210/endocr/bqab114/38496550/bqab114.pdf", "content-type": "application/pdf", "content-version": "am", "intended-application": "syndication" }, { "URL": "https://academic.oup.com/endo/article-pdf/162/8/bqab114/41810651/bqab114.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication" }, { "URL": "https://academic.oup.com/endo/article-pdf/162/8/bqab114/41810651/bqab114.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "80", "original-title": [], "prefix": "10.1210", "published": { "date-parts": [ [ 2021, 6, 5 ] ] }, "published-online": { "date-parts": [ [ 2021, 6, 5 ] ] }, "published-other": { "date-parts": [ [ 2021, 8, 1 ] ] }, "published-print": { "date-parts": [ [ 2021, 8, 1 ] ] }, "publisher": "The Endocrine Society", "reference": [ { "DOI": "10.1210/endocr/bqaa127", "article-title": "Estradiol, progesterone, immunomodulation, and COVID-19 outcomes", "author": "Mauvais-Jarvis", "doi-asserted-by": "crossref", "issue": "9", "journal-title": "Endocrinology", "key": "2021121717595546900_CIT0001", "volume": "161", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.04.479", "article-title": "Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)", "author": "Montopoli", "doi-asserted-by": "crossref", "first-page": "1040", "issue": "8", "journal-title": "Ann Oncol", "key": "2021121717595546900_CIT0002", "volume": "31", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.06.023", "article-title": "Does androgen deprivation therapy protect against severe complications from COVID-19?", "author": "Patel", "doi-asserted-by": "crossref", "first-page": "1419", "issue": "10", "journal-title": "Ann Oncol.", "key": "2021121717595546900_CIT0003", "volume": "31", "year": "2020" }, { "DOI": "10.1016/j.annonc.2020.06.005", "article-title": "On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2", "author": "Caffo", "doi-asserted-by": "crossref", "first-page": "1415", "issue": "10", "journal-title": "Ann Oncol.", "key": "2021121717595546900_CIT0004", "volume": "31", "year": "2020" }, { "DOI": "10.1111/jdv.17021", "article-title": "5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia", "author": "McCoy", "doi-asserted-by": "crossref", "first-page": "e243", "issue": "4", "journal-title": "J Eur Acad Dermatol Venereol.", "key": "2021121717595546900_CIT0005", "volume": "35", "year": "2021" }, { "article-title": "Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double-blinded, placebo-controlled trial", "author": "Cadegiani", "first-page": "e13492", "issue": "2", "journal-title": "Cureus.", "key": "2021121717595546900_CIT0006", "volume": "13", "year": "2021" }, { "DOI": "10.1073/pnas.2021450118", "article-title": "Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2", "author": "Qiao", "doi-asserted-by": "crossref", "first-page": "e2021450118", "issue": "1", "journal-title": "Proc Natl Acad Sci", "key": "2021121717595546900_CIT0007", "volume": "118", "year": "2021" }, { "DOI": "10.1038/s41467-021-21171-x", "article-title": "Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide", "author": "Li", "doi-asserted-by": "crossref", "first-page": "866", "issue": "1", "journal-title": "Nat Commun.", "key": "2021121717595546900_CIT0008", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.isci.2021.102254", "article-title": "Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19", "author": "Deng", "doi-asserted-by": "crossref", "first-page": "102254", "issue": "3", "journal-title": "Iscience.", "key": "2021121717595546900_CIT0009", "volume": "24", "year": "2021" }, { "DOI": "10.1096/fj.202100024R", "article-title": "Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection", "author": "Degauque", "doi-asserted-by": "crossref", "first-page": "e21577", "issue": "5", "journal-title": "Faseb J.", "key": "2021121717595546900_CIT0010", "volume": "35", "year": "2021" }, { "DOI": "10.3389/fimmu.2018.00794", "article-title": "Androgen-induced immunosuppression", "author": "Gubbels Bupp", "doi-asserted-by": "crossref", "first-page": "794", "journal-title": "Front Immunol.", "key": "2021121717595546900_CIT0011", "volume": "9", "year": "2018" }, { "DOI": "10.1111/andr.12821", "article-title": "Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients", "author": "Rastrelli", "doi-asserted-by": "crossref", "first-page": "88", "issue": "1", "journal-title": "Andrology.", "key": "2021121717595546900_CIT0012", "volume": "9", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2021.11398", "article-title": "Association of circulating sex hormones with inflammation and disease severity in patients with COVID-19", "author": "Dhindsa", "doi-asserted-by": "crossref", "first-page": "e2111398", "issue": "5", "journal-title": "JAMA Netw Open.", "key": "2021121717595546900_CIT0013", "volume": "4", "year": "2021" }, { "DOI": "10.1016/j.ebiom.2021.103246", "article-title": "Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males", "author": "Baldassarri", "doi-asserted-by": "crossref", "first-page": "103246", "journal-title": "Ebiomedicine.", "key": "2021121717595546900_CIT0014", "volume": "65", "year": "2021" } ], "reference-count": 14, "references-count": 14, "relation": {}, "resource": { "primary": { "URL": "https://academic.oup.com/endo/article/doi/10.1210/endocr/bqab114/6293822" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Do Anti-androgens Have Potential as Therapeutics for COVID-19?", "type": "journal-article", "volume": "162" }